Scientific Sessions 2024  /  Celebrating a Century of Cardiovascular Science: From Prevention to Treatment, to Cure  /  Discussant: nex-z, also known as NTLA-2001
Logo

American Heart Association

  122
  0

Final ID:

Discussant: nex-z, also known as NTLA-2001

  • Griffin, Jan  ( MUSC , Charleston , South Carolina , United States )
  • Davis, Margot  ( UNIVERSITY OF BRITISH COLUMBIA , Vancouver , British Columbia , Canada )
  • Cuddy, Sarah  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
    • Author Disclosures:
    Jan Griffin: No Answer | Margot Davis: DO have relevant financial relationships ; Speaker:Pfizer:Active (exists now) ; Consultant:Alnylam:Past (completed) ; Advisor:Ionis:Past (completed) ; Consultant:Novo Nordisk:Past (completed) ; Researcher:AstraZeneca:Active (exists now) | Sarah Cuddy: DO have relevant financial relationships ; Advisor:Bridgebio:Active (exists now) ; Advisor:Ionis:Active (exists now) ; Advisor:Astra Zeneca:Active (exists now) ; Speaker:Pfizer:Active (exists now) ; Speaker:Novo Nordisk:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Celebrating a Century of Cardiovascular Science: From Prevention to Treatment, to Cure

Saturday, 11/16/2024 , 08:30AM - 09:45AM

Late-Breaking Science

More abstracts on this topic:
Nexiguran ziclumeran (nex-z, also known as NTLA-2001), an investigational in vivo CRISPR-based therapy for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM): interim report of the Phase 1 study

Fontana Marianna, Olbertz Joy, Zhu Peijuan, Boiselle Carri, Smith Derek, Leung Adia, Gutstein David, Sonderfan Alison, Walsh Liron, Gillmore Julian, Taubel Jorg, Gane Edward, Pilebro Bjorn, Adams David, Solomon Scott, Claggett Brian, Kachadourian Jessica, Rocha Ricardo

Tirzepatide for Patients With Heart Failure With Preserved Ejection Fraction and Obesity: the SUMMIT Trial

Packer Milton

More abstracts from these authors:
Do Emerging HFpEF Treatments Work? The Role of Non-disease Modifying Treatments including SGLT2i, MRAs, GLP1s, and implantable hemodynamic monitors in Cardiac Amyloidosis.

Cuddy Sarah, Griffin Jan

Novel Therapies in the Management of Cardiac Amyloidosis and Access to Care

Falk Rodney, Kittleson Michelle, Cuddy Sarah

You have to be authorized to contact abstract author. Please, Login
Not Available